Report F412b1a3

PO No :PO2959578327-400
Name : Mr.NITISH BHATIA :

Age/Gender : 20/Male Registration Date : 12-Dec-22 09:30 AM
Patient ID : OKH444452 Collection Date : 12/Dec/2022 09:06AM
Barcode ID / Order ID : D0438689 / 6243659 Sample Receive Date : 12/Dec/2022 11:27AM
Referred By : Dr. Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA Report Date : 12/Dec/2022 03:22PM
HAEMATOLOGY
FULL BODY HEALTH PACKAGE
Test Name Result Unit Bio. Ref. Interval Method
Glycosylated Hemoglobin (HbA1c) 5.2 % 4 - 5.6 HPLC

Estimated average glucose (eAG) 102.54 mg/dL Calculated
Comment:
Interpretation: HbA1c%
≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes
Adapted from American Diabetes Association.
Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.
Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.
Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.
Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.
• HPLC - High performance liquid chromatography
Page 1 of 17
PO No :PO2959578327-400
Sample Type : Whole Blood-EDTA Report Date : 12/Dec/2022 03:24PM
HAEMATOLOGY
Complete Blood Count

Hemoglobin 16 g/dL 13.0-17.0 Cyanide Free SLS
RBC 5.35 10^6/cu.mm 4.5 - 5.5 Impedance
HCT 46.9 % 40 - 50 Calculated
MCV 87.6 fL 83 - 101 RBC pulse measurement
MCH 29.9 pg 27 - 32 Calculated
MCHC 34.1 g/dL 31.5 - 34.5 Calculated
RDW-CV 13.2 % 11.5-14 Calculated
Total Leucocyte Count 7.63 10^3/µL 4 - 10 Impedance
Differential Leucocyte Count
Neutrophils 57.2 % 40-80 Flowcytometery DHHS/
Microscopy
Lymphocytes 35.4 % 20-40 Flowcytometery DHHS/
Microscopy
Monocytes 4.7 % 2-10 Flowcytometery DHHS/
Microscopy
Eosinophils 2.3 % 1-6 Flowcytometery DHHS/
Microscopy
Basophils 0.4 % 0-2 Impedance / Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 4.36 10^3/µL 2-7 Calculated
Absolute Lymphocyte Count 2.7 10^3/µL 1-3 Calculated
Absolute Monocyte Count 0.36 10^3/µL 0.2-1 Calculated
Absolute Eosinophil Count 0.18 10^3/µL 0.02-0.5 Calculated
Absolute Basophil Count 0.03 10^3/µL 0.02-0.1 Calculated
Platelet Count 258 10^3/µL 150-410 Impedance /Microscopy
MPV 10.2 fL 6.5 - 12 Calculated
PDW 18 fL 9-17 Calculated
Page 2 of 17
PO No :PO2959578327-400
Sample Type : Whole Blood-EDTA Report Date : 12/Dec/2022 03:24PM
HAEMATOLOGY
Comment:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts
are additionally being reported as absolute numbers of each cell in per unit volume of blood.
Test conducted on EDTA whole blood.
Page 3 of 17
PO No :PO2959578327-400
Sample Type : EDTA Report Date : 12/Dec/2022 01:25PM
HAEMATOLOGY
Erythrocyte Sedimentation Rate 9 mm/hr 0-10 Capillary Photometry
Comment:
ESR provides an index of progress of the disease and is widely used as an indicator of inflammation, infection, trauma, or
malignant diseases. Changes are more significant than a single abnormal test
It is specifically indicated to monitor the course or response to the treatment of diseases like rheumatoid arthritis,
tuberculosis bacterial endocarditis ,acute rheumatic fever ,Hodgkins disease,temporal arthritis , and systemic lupus
erythematosis; and to diagnose and monitor giant cell arteritis and polymyalgia rheumatica.
An elevated ESR may also be associated with many other conditions, including autoimmune disease, anemia,
infection,malignancy,pregnancy, multiple myeloma, menstruation, and hypothyroidism.
Although a normal ESR cannot be taken to exclude the presence of organic disease, its rate is dependent on various
physiologic and pathologic factors.
The most important component influencing ESR is the composition of plasma. High level of C-Reactive Protein, fibrinogen,
haptoglobin, alpha-1antitrypsin, ceruloplasmin and immunoglobulins causes the elevation of Erythrocyte Sedimentation
Rate.
Drugs that may cause increase ESR levels include: dextran, methyldopa, oral contraceptives, penicillamine, procainamide,
theophylline, and Vitamin A. Drugs that may cause decrease levels include: aspirin, cortisone, and quinine
"Test conducted on Whole Blood - EDTA "
Page 4 of 17
PO No :PO2959578327-400
Sample Type : Serum Report Date : 12/Dec/2022 01:18PM
BIOCHEMISTRY
Iron Studies, Basic

Iron Serum 114 µg/dL 65-175 Ferrozine
Unsaturated Iron Binding Capacity 297 µg/dL 111 - 343 Ferene
Total Iron Binding Capacity ( TIBC) 411 µg/dL 240 - 450 Calculated
Transferrin Saturation 27.68 % 16-50 Calculated
Comment:
Iron is an essential trace mineral element which forms an important component of hemoglobin, metallocompounds and Vitamin
A. Deficiency of iron is seen in iron deficiency and anaemia of chronic disorders.
Increased iron concentration are seen in hemolytic anaemias, hemochromatosis and acute liver disease. Serum Iron alone is
unreliable due to considerable physiologic diurnal variation in the results with highest values in the morning and lowest values in
the evening as well as variation in response to iron therapy .
Total Iron Binding capacity (TIBC) is a direct measure of the protein Transferrin which transports iron from the gut to storage
sites in the bone marrow. Increased levels of TIBC suggest that total iron body stores are low, increased concentration may be
the sign of Iron deficiency anaemia, polycythemia vera ,and may occur during the third trimester of pregnancy. Decreased levels
may be seen in hemolytic anaemia, hemochromatosis, chronic liver disease, hypoproteinemia ,malnutrition.
Unsaturated Iron Binding Capacity (UIBC) is increased in low iron state and decreased in high iron concentration such as
hemochromatosis. In case of anaemia of chronic disease the patient may be anaemic but has adequate iron reserve and a low
uIBC.
Transferrin Saturation occurs in Idiopathic hemochromatosis and Transfusional hemosiderosis where no unsaturated iron
binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of Transferrin.
Page 5 of 17
PO No :PO2959578327-400
BIOCHEMISTRY
Lipid Profile
Cholesterol - Total 188 mg/dL Adults: Enzymatic
Desirable <200,
Borderline High 200-239,
High >=240
Triglycerides 53 mg/dL Normal: <150, GPO
Borderline: 150 - 199,
High:200-499,
Very High>=500
Cholesterol - HDL 57 mg/dL Low(undesirable, high Elimination/catalase
risk):<40
High(desirable, low
risk):>=60
Cholesterol - LDL 121 mg/dL Desirable: <100 Calculated
Above desirable: 100-
129
Borderline high: 130-159
High: 160-189
Very high: >=190
Cholesterol- VLDL 11 mg/dl <30 Calculated
Cholesterol : HDL Cholesterol 3.3 Ratio Desirable : 3.5-4.5 Calculated
High Risk : >5
LDL : HDL Cholesterol 2.13 Ratio Desirable : 2.5-3.0 Calculated
High risk : >3.5
Non HDL Cholesterol 131 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220
Page 6 of 17
PO No :PO2959578327-400
BIOCHEMISTRY
Comment:
Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart
are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for Atherosclerotic
Cardiovascular Disease (ASCVD) risk factors, especially lipid profile. This should be done earlier if there is a family
history of premature heart disease, dyslipidemia, obesity, or other risk factors.
The LAI recommends LDL-C as the primary target and non-HDL-C as a co-primary target, for lipid-lowering therapy.
Non-HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL, IDL, VLDL & VLDL
remnants, Chylomicron remnants and Lp(a).
Apo B measurement is recommended in high-risk subjects after LDL-C and non-HDL-C goals have been achieved.
Additional testing for Apolipoprotein B, hsCRP, Lp(a ) and LP-PLA2 should be considered among patients with
moderate risk for ASCVD for risk refinement.
Updated 2020 risk stratification approach recommended by the Lipid Association of India
Risk Factors/Markers
Moderate-risk
Major ASCVD Risk Factors Other High risk features nonconventional risk
factors
1. Age ≥45 years in males and 1. Diabetes with 0-1 other major ASCVD Risk factors and no 1. Coronary calcium score
≥55 years in females evidence of target organ damage 100-299
2. Family history of premature
2. CKD Stage 3B or 4 2. Increased carotid IMT
ASCVD
3. Current cigarette smoking and 3. Familial hypercholesterolemia (other than familial 3. Lipoprotein (a) 20-49
tobacco use homozygous hypercholesterolemia mg/dL
4. High blood pressure 4. Extreme of a single risk factor 4. Impaired Fasting Glucose*
5. Increased waist
5. Low HDL-C 5. Coronary calcium score ≥300
circumference**
6. Apolipoprotein B ≥110
6. Non-stenotic carotid plaque
mg/dL
7. Lipoprotein (a) ≥50 mg/dL 7. hsCRP ≥2 mg/L***
Risk groups
Low risk Moderate risk High risk Very High risk Extremely High risk
Page 7 of 17
PO No :PO2959578327-400
BIOCHEMISTRY
2 Major
≥3 major ASCVD
ASCVD risk Pre-existing ASCVD Category A Category B
risk factor
factors
0-1 major
Low risk group 2 major ASCVD risk
ASCVD risk Diabetes ≥2 other CAD ≥1 feature of very high risk
≥1 moderate- factor with ≥1
factor and major risk factors or group or recurrent ACS (within
risk moderate-risk
Lifetime CVD evidence of target one year) despite LDL-C ≤50
nonconventional nonconventional risk
risk <30% organ damage mg/dL or polyvascular disease
risk factors factors
Lifetime CVD ≥1 other high risk Familial homozygous
risk ≥30% features Hypercholesterolemia
* A fasting blood sugar level from 100 to 125 mg/dl. It should be confirmed by repeat testing; **Waist circumference is to be
measured at the superior border of the iliac crest just after expiration. Increased waist circumference is defined as >90 cm
in men and >80 cm in women. If increased waist circumference is the only risk factor, it should again be measured after 6
months after initiating heart-healthy lifestyle measures; ***On two occasions at least 2 weeks apart. For reclassifying moderate
risk group only.
Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020
Risk groups Treatment Goals Consider Drug Therapy
LDL-C (mg/dL) Non-HDL (mg/dL) LDL-C (mg/dL) Non-HDL (mg/dL)
Extreme Risk Group Category A <50 (Optional goal ≤30) <80 (Optional goal ≤60) ≥50 ≥80
Extreme Risk Group Category B ≤30 ≤60 >30 >60
Very High Risk <50 <80 ≥50 ≥80
High Risk <70 <100 ≥70 ≥100
Moderate Risk <100 ≥100 ≥130
Low risk <100 ≥130* ≥160*
*After an adequate non-pharmacological intervention for at least 3 months
Page 8 of 17
PO No :PO2959578327-400
BIOCHEMISTRY
Liver Function Test

Bilirubin-Total 1.48 mg/dl 0.3–1.2 Vanadate oxidation
Bilirubin-Direct 0.47 mg/dl 0 - 0.3 Vanadate oxidation
Bilirubin-Indirect 1.01 mg/dL 0.1 - 1.0 Calculated
Protein, Total 7.50 g/dL 5.7-8.2 Biuret
Albumin 4.80 g/dL 3.2-4.8 BCG Dye Binding
Globulin 2.7 g/dl 1.8 - 3.6 Calculated
A/G Ratio 1.78 Ratio 0.8 - 2.1 Calculated
Aspartate Transaminase (SGOT) 20 U/L <34 Modified IFCC
Alanine Transaminase (SGPT) 11 U/L 10-49 Modified IFCC
SGOT/SGPT 1.82 Ratio <1 Calculated
Alkaline Phosphatase 85 U/L 46-115 IFCC Standardization
Gamma Glutamyltransferase (GGT) 17 U/L <73 Modified IFCC
Comment:
LFTS are based upon measurements of substances released from damaged hepatic cells into the blood that gives idea of
the Existence, Extent and Type of Liver damage. - Acute Hepatocellular damage: ALT & AST levels are sensitive index of
hepatocellular damage - Obstruction to the biliary tract,Cholestasis and blockage of bile flow:1) Serum Total Bilirubin
concentration 2) Serum Alkaline Phosphatase (ALP) activity 3) Gamma Glutamyl Transpeptidase (GGTP) 4) 5`-
Nucleotidase - Chronic liver disease: Serum Albumin concentration
Bilirubin results from the enzymatic breakdown of heme. Jaundice is a yellowish discoloration of the skin and mucous
membranes caused by hyperbilirubinemia.
Pre-hepatic or hemolytic jaundice - Abnormal red cells, antibodies,drugs and toxins,Hemoglobinopathies, Gilbert’s
syndrome, Crigler-Najjar syndrome
Hepatic or Hepatocellular jaundice-Viral hepatitis,toxic hepatitis, intrahepatic cholestasis
Post-hepatic jaundice -Extrahepatic cholestasis, gallstones, tumors of the bile duct, carcinoma of pancreas
In viral hepatitis and other forms of liver disease associated with acute hepatic necrosis, serum AST and ALT
concentrations are elevated even before the clinical signs and symptoms of disease appear.
ALT is the more liver-specific enzyme and elevations of ALT activity persist longer than AST activity.
Page 9 of 17
PO No :PO2959578327-400
BIOCHEMISTRY
Peak values of aminotransferase activity occur between the seventh and twelfth days. Activities then gradually decrease,
reaching normal activities by the third to fifth week. Peak activities bear no relationship to prognosis and may fall with
worsening of the patient's condition.
Aminotransferase activities observed in cirrhosis vary with the status of the cirrhotic process and range from the upper
reference limit to four to five times higher, with an AST/ALT ratio greater than 1. The ratio's elevation can reflect the grade
of fibrosis in these patients. Slight or moderate elevations of both AST and ALT activities have been observed after
administration of various medications and chronic hepatic injury such as (1) hemochromatosis, (2) Wilson disease, (3)
autoimmune hepatitis, (4) primary biliary cirrhosis, (5) sclerosing cholangitis, and (6) a1-antitrypsin deficiency.
AST activity also is increased in acute myocardial infarction, progressive muscular dystrophy and dermatomyositis, reaching
concentrations up to eight times the upper reference limit.Slight to moderate AST elevations are noted in hemolytic
disease.
GGT is a sensitive indicator of the presence of hepatobiliary disease, being elevated in most subjects with liver disease
regardless of cause. Increased concentrations of the enzyme are also found in serum of subjects receiving anticonvulsant
drugs, such as phenytoin and phenobarbital.
Page 10 of 17
PO No :PO2959578327-400
BIOCHEMISTRY
Kidney Panel with GFR

Blood Urea Nitrogen 15 mg/dL 9.0-23.0 Urease with GLDH
Urea 32.10 mg/dL 19.26-49.22 Calculated
Creatinine 0.72 mg/dL 0.70-1.30 Alkaline picrate - kinetic
BUN/Creatinine Ratio 20.8 Ratio 12:1 - 20:1 Calculated
Calcium 10.0 mg/dL 8.7-10.4 Arsenazo III
Uric Acid 3.5 mg/dL 3.7-9.2 Uricase/Peroxidase
Glomerular Filtration Rate 134 mL/min/1.73m2 Calculated
Interpretation:
The Recommended method for estimating GFR in adults(>=18yrs) from the National Kidney Foundation is the 2021 CKD-EPI
equations.Estimates GFR from serum creatinine, age and sex.
Criteria for CKD

Either of the following present for > 3 months
Albuminuria
Urine sediment abnormalities
Electrolyte and other
abnormalities due to tubular
disorders
Markers of kidney damage (one
or more) Abnormalities detected by
histology
Structural abnormalities
detected by imaging
History of kidney
transplantation
Decreased GFR GFR <60 ml/min/1.73 sq.m
Abbreviations: CKD, chronic kidney disease; GFR, glomerular
filtration rate
Page 11 of 17
PO No :PO2959578327-400
Immunology
Thyroid Profile
T3, Total 0.86 ng/mL 0.86-1.92 CLIA
T4, Total 8.6 µg/dl 4.5-12.6 CLIA
Thyroid Stimulating Hormone - Ultra 1.282 uIU/ml 0.48-4.17 CLIA
Sensitive
Comment:
Below mentioned are the guidelines for pregnancy related reference ranges for TSH, total T3 & Total T4.
Pregnancy
TSH (μIU/mL) (as per
American Thyroid Total T3 (ng/mL) Total T4(μg/dL)
Association )
1st trimester 0.1-2.5 0.81-1.90 7.33-14.8
2nd trimester 0.2-3.0 1.00-2.60 7.93-16.1
3rd trimester 0.3-3.0 1.00-2.60 6.95-15.7
TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
Total T3 & T4 concentrations are altered by physiological or pathological changes in thyroxine binding globulin (TBG)
capacity .
The determination of free T3 & free T4 has the advantage of being independent of changes in the concentrations and
binding properties of the binding proteins.
Changes in thyroid status are typically associated with concordant changes in T3, T4 and TSH levels.
Unexpectedly abnormal or discordant thyroid test values may be seen with some rare, but clinically significant conditions
such as central hypothyroidism, TSH-secreting pituitary tumors, thyroid hormone resistance, or the presence of
heterophilic antibodies (HAMA) or thyroid hormone autoantibodies.
For diagnostic purposes, results should be used in conjunction with other data.
Page 12 of 17
PO No :PO2959578327-400
Immunology
TSH T3 T4 Interpretation
High Normal Normal Subclinical Hypothyroidism
Low Normal Normal Subclinical Hyperthyroidism
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low Hypothyroidism
Page 13 of 17
PO No :PO2959578327-400
Immunology
Vitamin D (25-OH) 24.6 ng/mL Deficiency:< 20, CLIA

Insufficiency:20-29,
Sufficiency:30 - 100,
Toxicity possible:> 100
Comment:
Vitamin D is a fat-soluble steroid prohormone involved in the intestinal absorption of calcium and the regulation of calcium
homeostasis.
Two forms of vitamin D are biologically relevant - vitamin D3 (Cholecalciferol) and vitamin D2 (Ergocalciferol).
Both vitamins D3 and D2 can be absorbed from food but only an estimated 10-20perc. of vitamin D is supplied through
nutritional intake.
Vitamin D is converted to the active hormone 1,25-(OH)2-vitamin D (Calcitriol) through two hydroxylation reactions. The
first hydroxylation converts vitamin D into 25-OH vitamin D and occurs in the liver. The second hydroxylation converts 25-
OH vitamin D into the biologically active 1,25-(OH)2-vitamin D and occurs in the kidneys as well as in many other cells of
the body.
Most cells express the vitamin D receptor and about 3perc. of the human genome is directly or indirectly regulated by the
vitamin D endocrine system.
The major storage form of vitamin D is 25-OH vitamin D and is present in the blood at up to 1,000 fold higher
concentration compared to the active 1,25-(OH)2-vitamin D. 25-OH vitamin D has a half-life of 2-3 weeks vs. 4 hours for
1,25-(OH)2-vitamin D. Therefore, 25-OH vitamin D is the analyte of choice for determination of the vitamin D status.
Risk factors for vitamin D deficiency include low sun exposure, inadequate intake, decreased absorption, abnormal
metabolism, vitamin D resistance and and liver or kidney diseases.
Vitamin D deficiency is a cause of secondary hyperparathyroidism and diseases resulting in impaired bone metabolism (like
rickets, osteomalacia).
Recently, many chronic diseases such as cancer, high blood pressure, osteoporosis and several autoimmune diseases
have been linked to vitamin D deficiency.
Utility Quantitative determination of 25-hydroxyvitamin D (25-OH vitamin D).
Page 14 of 17
PO No :PO2959578327-400
Immunology
Vitamin B12 435.0 pg/ml 211 - 911 CLIA
Comment:
Vitamin B12 along with folate is essential for DNA synthesis and myelin formation.
Decreased levels a r e s e e n i n a n a e m i a , t e r m p r e g n a n c y , v e g e t a r i a n d i e t , i n t r i n s i c f a c t o r d e f i c i e n c y , p a r t i a l
gastrectomy/ileal damage, celiac disease, oral contraceptive use, parasitic infestation, pancreatic deficiency, treated
epilepsy, smoking, hemodialysis and advanced age.
Increased levels are seen in renal failure, hepatocelluar disorders, myeloproliferative disorders and at times with excess
supplementation of vitamins pills.
Page 15 of 17
PO No :PO2959578327-400
Sample Type : Urine Report Date : 12/Dec/2022 03:03PM
CLINICAL PATHOLOGY
Urine Routine & Microscopy

Colour PALE YELLOW Pale Yellow
Appearance CLEAR Clear
Specific gravity 1.025 1.003 - 1.035 pKa change
pH 6.0 4.6 - 8.0 Double Indicator
Glucose NEGATIVE Negative GOD-POD
Protein NEGATIVE Negative Protein Error Principle
Ketones NEGATIVE Negative Nitroprusside
Blood NEGATIVE Negative Peroxidase
Bilirubin NEGATIVE Negative Diazonium
Urobilinogen NORMAL Normal Ehrlich
Leucocyte Esterase NEGATIVE Negative Pyrrole
Nitrite NEGATIVE Negative P-arsanilic acid
Pus cells 1-2 /hpf 0-5 Microscopy
Red Blood Cells NIL /hpf 0-2 Microscopy
Epithelial cells 1-2 /hpf Few Microscopy
Casts NIL /lpf Nil Microscopy
Crystals NIL Nil Microscopy
Yeast NIL Nil Microscopy
Bacteria NIL Nil Microscopy
Comment:
•Note: Pre-test condition to be observed while submitting the sample-first void, mid stream urine, collected in a clean, dry, sterile
container is recommended for routine urine analysis, avoid contamination with any discharge from vaginal, urethra, perineum,
Avoid prolonged transit time & undue exposure to sunlight.
•During interpretation, points to be considered are Negative nitrite test does not exclude the urinary tract infections. Trace
proteinuria can be seen with many physiological conditions like prolonged recumbency, exercise, high protein diet. False positive
reactions for bile pigments, proteins, glucose and nitrites can be caused by peroxidase like activity by disinfectants, therapeutic
dyes, ascorbic acid and certain drugs.• Urine microscopy is done in centrifuged urine specimens
Page 16 of 17
PO No :PO2959578327-400
Sample Type : Urine Report Date : 12/Dec/2022 03:03PM
CLINICAL PATHOLOGY
*** End Of Report ***
Page 17 of 17

Report F412b1a3

Uploaded by

Copyright:

Available Formats

Report F412b1a3

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Report F412b1a3

Uploaded by

Copyright:

Available Formats

PO No :PO2959578327-400

Name : Mr.NITISH BHATIA :

Glycosylated Hemoglobin (HbA1c) 5.2 % 4 - 5.6 HPLC

Adapted from American Diabetes Association.

• HPLC - High performance liquid chromatography

Complete Blood Count

Erythrocyte Sedimentation Rate 9 mm/hr 0-10 Capillary Photometry

"Test conducted on Whole Blood - EDTA "

Iron Studies, Basic

Liver Function Test

Kidney Panel with GFR

Criteria for CKD

Vitamin D (25-OH) 24.6 ng/mL Deficiency:< 20, CLIA

Utility Quantitative determination of 25-hydroxyvitamin D (25-OH vitamin D).

Vitamin B12 435.0 pg/ml 211 - 911 CLIA

Urine Routine & Microscopy

* End Of Report *

You might also like